SABCS 2021 | Predicted sensitivity to ET (SET2,3 index): results of an analysis of the SWOG S8814 trial

The SWOG trial S8814 (NCT00929591) randomized postmenopausal patients with pathologic lymph node-positive HR+ breast cancer to receive adjuvant anthracycline-based chemotherapy followed by tamoxifen endocrine therapy for 5 years, versus tamoxifen alonel the 2-gene Breast Recurence Score assay was determined to predict chemotherapy benefit in patients with a higher Recurrence Score. In this interview, Corey Speers, MD, PhD, University of Michigan Medicine, Ann Arbor, MI, discusses the results of an analysis of SWOG S8814 which evaluated the predicted sensitivity to endocrine therapy (ET) (SET2,3) index. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.